This study will assess time to discontinuation due to lack of tolerability among patients with schizophrenia receiving LY2140023, given orally twice daily for 24 weeks, versus those on atypical antipsychotic standard-of-care treatment. Lack of tolerability is defined as discontinuation due to adverse events (AEs).

• Drug: LY2140023
  80mg, oral tablets,twice daily: 40 mg in the morning, 40 mg in the evening, for 24 weeks. The dose may be adjusted to a minimum of 40mg or a maximum of 160mg.
• Drug: aripiprazole
  10mg, oral tablets, once a day in the evening for three days. Followed by a dose increase to 20mg, 2-10mg oral tablets,once a day in the evening, for 23 weeks and 4 days. The dose may be adjusted to a minimum of 10mg or a maximum of 30mg (3-10mg oral tablets).
• Drug: olanzapine
  10mg dose (2-5mg oral tablets) once every evening, for 3 days. Followed by an increase to 15mg (3-5mg oral tablets) once every evening, for 23 weeks and 4 days. The dose may be adjusted to a minimum of 10mg or a maximum of 20mg (4-5mg oral tablets).
  Other Names:

  • Zyprexa
  • LY170053
• Drug: risperidone
  2mg dose, 2-1mg oral tablets, given once or twice a day for 3 days. Followed by an increase to 4mg (4-1mg tablets), given once or twice a day, for 23 weeks and 4 days. The dose may be adjusted to a minimum of 2mg/day or a maximum of 6mg/day (6-1mg tablets).

• LY2140023: Experimental
  Intervention: Drug: LY2140023
• aripiprazole: Active Comparator
  Intervention: Drug: aripiprazole
• olanzapine: Active Comparator
  Intervention: Drug: olanzapine
• risperidone: Active Comparator
  Intervention: Drug: risperidone

Inclusion Criteria:

• Clinical diagnosis of schizophrenia
• Patients, in the investigator's opinion, must require a switch to another antipsychotic medication as clinically indicated or initiation of an antipsychotic agent
• Patients must be willing and able to be hospitalized, or to remain hospitalized (if already hospitalized), for up to 17 days
• The investigator expects, at the time of enrollment, that the patient will be able to be discharged from the hospital after the first 2 weeks of active treatment
• Disease symptoms must meet a certain range as assessed by the clinician
• Patients must have evidence of functional impairment (i.e. social or vocational deficiency)
• Patients must be considered reliable, have a level of understanding sufficient to perform all tests and examinations required by the protocol, and be willing to perform all study procedures
• Patients must be able to understand the nature of the study and have given their informed consent

Exclusion Criteria:

• Patients who are actively suicidal
• Patients who are pregnant or nursing
• Patients who have had electroconvulsive therapy (ECT) within 3 months of screening or who will have ECT at any time during the study
• Patients with uncorrected narrow-angle glaucoma, seizures, uncontrolled diabetes, certain diseases of the liver, uncontrolled thyroid condition or other serious or unstable illnesses
• Patients with Parkinson's disease, psychosis related to dementia or related disorders
• Patients with known Human Immunodeficiency Virus positive (HIV+) status